{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:58:49Z","timestamp":1790438329368,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"The Natural Sciences and Engineering Research Council of Canada (NSERC)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins & Other Lipid Mediators"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.prostaglandins.2014.10.005","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T05:51:14Z","timestamp":1415080274000},"page":"19-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease"],"prefix":"10.1016","volume":"116-117","author":[{"given":"Naser H.M.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Gregoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessay G.","family":"Devassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamio","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuko","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold M.","family":"Aukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0005","first-page":"86","article-title":"Autosomal dominant polycystic kidney disease and transplantation","volume":"14","author":"Niemczyk","year":"2009","journal-title":"Ann Transplant"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0010","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14656566.2014.903923","article-title":"Pharmacological management of polycystic kidney disease","volume":"15","author":"Wuthrich","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/ki.2014.120","article-title":"Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease","author":"Spithoven","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.physiol.70.113006.100614","article-title":"Physiological regulation of prostaglandins in the kidney","volume":"70","author":"Hao","year":"2008","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0025","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2006040343","article-title":"Role of microsomal prostaglandin E synthase 1 in the kidney","volume":"18","author":"Francois","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0030","first-page":"F659","article-title":"Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells","volume":"271","author":"Jensen","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0035","doi-asserted-by":"crossref","first-page":"F1782","DOI":"10.1152\/ajprenal.00513.2006","article-title":"COX-2 activity determines the level of renin expression but is dispensable for acute upregulation of renin expression in rat kidneys","volume":"292","author":"Matzdorf","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.prostaglandins.2012.03.005","article-title":"Prostaglandin E 2 stimulates cystogenesis through EP4 receptor in IMCD-3 cells","volume":"98","author":"Elberg","year":"2012","journal-title":"Prostaglandins Other Lipid Mediators"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0045","doi-asserted-by":"crossref","first-page":"F1622","DOI":"10.1152\/ajprenal.00036.2007","article-title":"EP 2 receptor mediates PGE 2-induced cystogenesis of human renal epithelial cells","volume":"293","author":"Elberg","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0050","doi-asserted-by":"crossref","first-page":"F381","DOI":"10.1152\/ajprenal.1995.269.3.F381","article-title":"Anion secretion drives fluid secretion by monolayers of cultured human polycystic cells","volume":"269","author":"Mangoo-Karim","year":"1995","journal-title":"Am J Physiol Renal Fluid Electrolyte Physiol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0055","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/mnfr.201300332","article-title":"Renal cyclooxygenase and lipoxygenase products are altered in polycystic kidneys and by dietary soy protein and fish oil treatment in the Han:SPRD-Cy rat","volume":"58","author":"Ibrahim","year":"2014","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0060","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3181\/0811-RM-315","article-title":"Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease","volume":"234","author":"Peng","year":"2009","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0065","doi-asserted-by":"crossref","first-page":"F897","DOI":"10.1152\/ajprenal.00332.2005","article-title":"Selectivity of cyclooxygenase isoform activity and prostanoid production in normal and diseased Han:SPRD-cy rat kidneys","volume":"290","author":"Warford-Woolgar","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0070","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jnutbio.2011.04.016","article-title":"A dietary conjugated linoleic acid treatment that slows renal disease progression alters renal cyclooxygenase-2-derived prostanoids in the Han: SPRD-cy rat","volume":"23","author":"Wakefield","year":"2012","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11745-013-3859-2","article-title":"Renal cyclooxygenase products are higher and lipoxygenase products are lower in early disease in the pcy mouse model of adolescent nephronophthisis","volume":"49","author":"Yamaguchi","year":"2014","journal-title":"Lipids"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0080","doi-asserted-by":"crossref","first-page":"F821","DOI":"10.1152\/ajprenal.00257.2006","article-title":"Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease","volume":"293","author":"Sankaran","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0085","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1007\/s11033-012-1611-2","article-title":"Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF\/Raf\/MAPK\/ERK signaling pathway","volume":"39","author":"Xu","year":"2012","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0090","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1046\/j.1523-1755.2002.00520.x","article-title":"Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension","volume":"62","author":"Cheng","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0095","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1046\/j.1523-1755.2000.00093.x","article-title":"A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats","volume":"57","author":"Wang","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0100","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1592\/phco.22.15.1317.33472","article-title":"Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature","volume":"22","author":"Morales","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0105","doi-asserted-by":"crossref","unstructured":"Wu KK. Aspirin and salicylate. An old remedy with a new twist. Circulation 2000;102:2022\u20133.","DOI":"10.1161\/01.CIR.102.17.2022"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0110","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ki.1994.253","article-title":"Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease","volume":"46","author":"Schafer","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ki.1979.2","article-title":"Nephron obstruction in nordihydroguaiaretic acid-induced renal cystic disease","volume":"15","author":"Evan","year":"1979","journal-title":"Kidney Int"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0120","first-page":"93","article-title":"A cystic nephropathy induced by nordihydroguaiaretic acid in the rat. Light and electron microscopic investigations","volume":"23","author":"Goodman","year":"1970","journal-title":"Lab Invest"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0125","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0130","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/jn\/123.11.1939","article-title":"AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet","volume":"123","author":"Reeves","year":"1993","journal-title":"J Nutr"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0135","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1095\/biolreprod58.5.1211","article-title":"The lipoxygenase inhibitor, nordihydroguaiaretic acid, inhibits ovulation and reduces leukotriene and prostaglandin levels in the rat ovary","volume":"58","author":"Mikuni","year":"1998","journal-title":"Biol Reprod"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0140","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0378-4320(97)00080-8","article-title":"A role for lipoxygenase metabolites of arachidonic acid in porcine ovulation","volume":"49","author":"Downey","year":"1998","journal-title":"Anim Reprod Sci"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0145","unstructured":"Health USDo, Services H, Food, Administration D, Evaluation CfD, CDER R. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; 2005."},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0150","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/mnfr.201000558","article-title":"Distinctive effects of plant protein sources on renal disease progression and associated cardiac hypertrophy in experimental kidney disease","volume":"55","author":"Aukema","year":"2011","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0155","doi-asserted-by":"crossref","first-page":"e81480","DOI":"10.1371\/journal.pone.0081480","article-title":"Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease","volume":"8","author":"Yoshihara","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1523-1755.2000.00835.x","article-title":"Modification of polycystic kidney disease and fatty acid status by soy protein diet","volume":"57","author":"Ogborn","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0165","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/1711125a0","article-title":"Determination of creatinine by the Jaffe reaction","volume":"171","author":"Hervey","year":"1953","journal-title":"Nature"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0170","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0076-6879(07)32003-X","article-title":"Detection and quantitation of eicosanoids via high performance liquid chromatography-electrospray ionization-mass spectrometry","volume":"432","author":"Deems","year":"2007","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0180","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cmdc.201100460","article-title":"Aspirin analogues as dual cyclooxygenase-2\/5-lipoxygenase inhibitors: Synthesis, nitric oxide release, molecular modeling, and biological evaluation as anti-inflammatory agents","volume":"7","author":"Kaur","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0185","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/ki.2013.501","article-title":"Renal cyst growth is the main determinant for hypertension and concentrating deficit in Pkd1-deficient mice","volume":"85","author":"Fonseca","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0190","doi-asserted-by":"crossref","first-page":"e92232","DOI":"10.1371\/journal.pone.0092232","article-title":"Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0195","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2215\/CJN.00910306","article-title":"Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease","volume":"2","author":"Torres","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0205","first-page":"4","article-title":"Proinflammatory and immunoregulatory roles of eicosanoids in T cells","author":"Lone","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10157-012-0741-0","article-title":"Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies","volume":"17","author":"Mochizuki","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0215","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MNH.0b013e3283262ab0","article-title":"Advances in the pathogenesis and treatment of polycystic kidney disease","volume":"18","author":"Patel","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0220","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0225","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev.physiol.63.1.579","article-title":"G protein-coupled prostanoid receptors and the kidney","volume":"63","author":"Breyer","year":"2001","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0230","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1523-1755.2000.00931.x","article-title":"Eicosapentaenoic acid suppresses PDGF-induced DNA synthesis in rat mesangial cells: involvement of thromboxane A2","volume":"57","author":"Schmitz","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0235","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-13-2563","article-title":"Aspirin and colorectal cancer: back to the future","volume":"20","author":"Tougeron","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0240","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000001","article-title":"Warfarin and aspirin use for stroke prevention among patients with atrial fibrillation: The US National Health and Wellness Survey","author":"Goren","year":"2013","journal-title":"Am J Ther"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0245","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.amjcard.2011.02.325","article-title":"Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin","volume":"107","author":"Bartolucci","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0250","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ejca.2012.09.030","article-title":"Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level","volume":"49","author":"Veitonm\u00e4ki","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0255","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1056\/NEJM198402023100502","article-title":"Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin","volume":"310","author":"Ciabattoni","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0260","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/00045391-199511000-00006","article-title":"Effects of misoprostol on nonsteroidal anti-inflammatory drug-induced renal insufficiency in patients with stable chronic renal failure: a double-blind, crossover study","volume":"2","author":"Whelton","year":"1995","journal-title":"Am J Ther"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0265","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1370\/afm.1302","article-title":"Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States","volume":"9","author":"Plantinga","year":"2011","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0270","doi-asserted-by":"crossref","first-page":"568","DOI":"10.7326\/0003-4819-112-8-568","article-title":"Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison","volume":"112","author":"Whelton","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0275","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJM199412223312502","article-title":"Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs","volume":"331","author":"Perneger","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0280","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0285","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1159\/000104836","article-title":"Late dietary intervention limits benefits of soy protein or flax oil in experimental polycystic kidney disease","volume":"106","author":"Sankaran","year":"2007","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0290","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1159\/000153244","article-title":"Effects of dietary conjugated linoleic acid in advanced experimental polycystic kidney disease","volume":"110","author":"Scatliff","year":"2008","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0295","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0014-4827(03)00282-9","article-title":"Nordihydroguaiaretic acid, an antioxidant, inhibits transforming growth factor-beta activity through the inhibition of Smad signaling pathway","volume":"289","author":"Lee","year":"2003","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0300","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0090-6980(99)00047-7","article-title":"Suppression of oxytocin-induced prostaglandin F2alpha release after intra-uterine nordihydroguariaretic acid administration in ewes","volume":"60","author":"Cooke","year":"2000","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0305","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0041-0101(02)00203-9","article-title":"Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse","volume":"40","author":"Lambert","year":"2002","journal-title":"Toxicon"},{"key":"10.1016\/j.prostaglandins.2014.10.005_bib0310","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3945\/jn.113.177360","article-title":"Dietary linoleic acid and alpha-linolenic acid differentially affect renal oxylipins and phospholipid fatty acids in diet-induced obese rats","volume":"143","author":"Caligiuri","year":"2013","journal-title":"J Nutr"}],"container-title":["Prostaglandins & Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882314000707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882314000707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T20:37:18Z","timestamp":1565987838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882314000707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":62,"alternative-id":["S1098882314000707"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2014.10.005","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2014.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}